



January 23, 2012

**Subject: Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST) Preliminary Report for November 2011**

Dear Participants:

Attached you will find the preliminary susceptibility testing results for the cultures of *M. tuberculosis* sent to your laboratory in November 2011. (You may also access the report at <http://wwwn.cdc.gov/mpep/mtbds.aspx>) These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the CDC recommends the broth-based methods for routine *M. tuberculosis* drug susceptibility testing, this preliminary report provides the results obtained by using the reference agar proportion method, except in the case of pyrazinamide, where BACTEC MGIT 960 is the reference method. Participants should use the equivalent critical concentrations for testing methods, as defined in CLSI M-24A standards, to determine their results.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. Subsequently, a detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) *M. tuberculosis* complex isolates will be emailed.

For additional information or to comment on this report, you may call Suzette Brown at 1-888-465-6062 or 404 718-4603 or email [mtbntmdst@cdc.gov](mailto:mtbntmdst@cdc.gov) or [snp4@cdc.gov](mailto:snp4@cdc.gov). You may also contact Beverly Metchock at 404 639-1285 or email [BMetchock@cdc.gov](mailto:BMetchock@cdc.gov).

We appreciate your continued interest and participation in the CDC Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST).

Sincerely yours,

Suzette A. Brown, MS  
Project Coordinator  
Model Performance Evaluation Program  
NCEZID/DPEI/LSDB  
Centers for Disease Control and Prevention  
Ph : 404 718-4603  
email : [snp4@cdc.gov](mailto:snp4@cdc.gov)

**Preliminary Report**

**Susceptibility Testing Results:  
*M. tuberculosis* Isolates  
Panel Shipment November 7, 2011**

<b>Isolate</b>	<b>Susceptibility Testing Results</b>
F	Resistant to Rifampin (RIF)
G	Resistant to Isoniazid (INH) Resistant to Streptomycin (SM)
H	Resistant to Streptomycin (SM) Resistant to Pyrazinamide (PZA)
I	Susceptible to first-and second-line drugs
J	Resistant to Isoniazid (INH) Resistant to Ethambutol (EMB) Resistant to Kanamycin (KM) Resistant to Capreomycin (CAP) Resistant to Amikacin (AMK)